Sign in

Trial result ·

Phase I results of a multicenter, open-label, dose de-escalation and expansion study of gemcitabine and cisplatin with ivosidenib or pemigatinib for advanced cholangiocarcinoma.

Written based on 1 research study on PubMed, searched on 3 Nov 2026.

What was studied

This early-stage trial tested ivosidenib or pemigatinib added to gemcitabine and cisplatin. The people had advanced bile duct cancer. Cholangiocarcinoma is a rare bile duct cancer with a poor prognosis. Tumors had IDH1 mutations or FGFR2 fusions. People whose cancer had not grown after standard chemotherapy joined. The main aims were safety, tolerability and the maximum tolerated dose.

What they found

Enrollment began in January 2020. The study ended early in November 2022. Most people were in the ivosidenib arm, called Arm A. Only one was in the pemigatinib arm. Enrollment there was limited by trouble finding FGFR2-positive patients. In Arm A, one patient had a partial response. The rest had stable disease. Median progression-free survival was 15.4 months. Median overall survival was 22.9 months.

What it means for patients

The authors say adding ivosidenib to gemcitabine and cisplatin showed a challenging safety profile. They say efficacy results must be read with caution. They say more research and dose optimization are warranted.

Why it is not certain yet

The study closed early. Few people enrolled. The authors cite selection bias and small sample size. Efficacy numbers come from Arm A only. Severe toxicities of grade 3 or higher were seen in most Arm A patients.

The registered trial

The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.

Source

Phase I results of a multicenter, open-label, dose de-escalation and expansion study of gemcitabine and cisplatin with ivosidenib or pemigatinib for advanced cholangiocarcinoma.

PubMed · PMID 41678089

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Liver and biliary tract cancer publications